The primary outcome measure of the trial was negative urine tests for cocaine for the last three weeks of the nine-week trial.
A total of 18 subjects fulfilled the criteria for the primary outcome measure. Of these, 14 (28%) were treated with vigabatrin versus four (7.6%) who were treated with placebo. A logistic regression utilizing years of cocaine use and average amount per day at baseline yielded statistically significant treatment differences. The p-value was 0.009.
There were no serious adverse events reported in this trial.
"These positive results demonstrate that there is hope for the millions of individuals who suffer from the life threatening consequences of this terrible illness," said Dr. Brodie. "It also demonstrates how a dedicated team of basic scientists and clinicians who persevere in a mission can produce important medical advances by taking an idea from the bench to the community."
Investor Conference Call
Catalyst will hold a conference call today to discuss the trial
results. Investors wishing to participate may access the live call as
Date: December 7, 2007
Time: 11:00 AM ET
Dial-in numbers: 888-802-2266 (U.S. only) or 913-312-1294
Live webcast: http://www.catalystpharma.com
A recording of the conference call will be available two hours after
completion until Wednesday, December 12, 2007 at 11:59 PM ET at
888-203-1112 (U.S. only) or 719-457-0820. The
|SOURCE Catalyst Pharmaceutical Partners, Inc.|
Copyright©2007 PR Newswire.
All rights reserved